Every year more and more are approved – a plethora of PLA codes for laboratories to keep track of and manage. So, what are they and what do you need to know about the latest changes that could cause confusion…or worse? With over 70 new PLA codes effective in the last year alone, it’s time to solidify knowledge and understanding of this murky code set. Let’s take a look and break down some of the basics.
PLA codes were first established by the American Medical Association (AMA) CPT® Editorial Panel as alphanumeric CPT codes that provide corresponding descriptors for laboratories or manufacturers. Why? These entities were seeking a way to more specifically identify their testing. The creation was also a direct answer to the implementation of the Protecting Access to Medicare Act of 2014 (PAMA). In the final rule for PAMA implementation, the Centers for Medicare and Medicaid Services (CMS) established the definition of advanced diagnostic laboratory tests (ADLTs) as tests created and offered by a single lab that use a unique algorithm to analyze multiple DNA, RNA, or protein markers, and which provide new clinical diagnostic information that can’t be obtained by any other test.
Tests assigned to PLA codes must meet specific criteria:
Note: Limiting factors exist which determine what laboratory has the right to use certain PLA codes or the manufacturer-specific lab test they are assigned to, but that is all in the name, “proprietary.”
If you aren’t yet familiar with it, you should be. As defined by PAMA, the PLA code section was developed to include ADLTs and clinical diagnostic laboratory tests (CDLTs) for procedures based on human gene analysis. Recently, however, the language describing PLA codes is opening the door for the approval of new codes for procedures not limited to human gene-based analysis. With new PLA codes effective for chemistry testing, drug analysis, microbiology and more, welcome to a coding world where certain tests with existing Category 1 CPT codes will also have a manufacturer-specific PLA code. This crossover is sure to create a scenario with high risk for confusion, miscoding and claims denials.
Here are some quick guidelines that may help dodge this tricky situation and secure your confidence navigating PLA codes.
Unfortunately, it should be noted even with the existence AND correct application of the PLA code, this is not an indication that the code will be covered or separately paid. When it comes to PLA codes, many commercial payers require prior authorization to assess whether medical indications for the procedure were followed by looking at both the diagnosis and code.
Prior authorization has some further restrictions. Payers specifically state that laboratories are restricted from obtaining clinical authorization on behalf of the ordering physician. Even more, their policies outline that should a laboratory be found supporting any portion of the authorization process, the payer holds the right of deeming the action a violation of participation.
The financial liabilities that fall under the prior authorization process are similar to that of the Medicare Advance Beneficiary Notice. Should a laboratory service not be authorized but performed, the service shall be denied and considered the financial liability of the laboratory. This means that the cost of testing is not allowed to be passed on to the patient. All and all these are serious consequences that any laboratory should seek to avoid since the uncertainty with PLA won’t be ending anytime soon, if ever…
Let me start with some follow-up on a topic I have written about before: the widening of the use of “against medical advice” (AMA) to
A few weeks ago, Dr. Ron (Ronald Hirsch, MD) wrote about a situation in which members of a utilization review (UR) staff were uncomfortable with
Please log in to your account to comment on this article.
Breast biopsy procedures may be clinically straightforward but accurately translating them into compliant billing can be anything but. In this focused webcast, Shawn Blackburn, CPC, CPMA, CIC, CRC, CCS-P breaks down how imaging guidance, lesion count, laterality, and payer expectations all impact how these procedures should be reported. Through clear explanations and real-world scenarios, you’ll gain practical insight into aligning clinical workflows with billing requirements, avoiding common pitfalls, and ensuring your documentation supports accurate reimbursement and compliance.
Gain clarity and confidence in OB‑GYN coding with this expert‑led webcast featuring Sherri L. Clayton, RHIT, CSS. You’ll learn how to apply global maternity package rules accurately, select the right CPT codes for procedures and visits, and identify documentation gaps that lead to denials. With practical guidance and real examples, this session helps you strengthen compliance, reduce audit risk, and ensure accurate reimbursement for women’s health services.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Traditional utilization management models can no longer keep pace with regulatory shifts, payer scrutiny, and operational pressures. In this webcast, Tiffany Ferguson, LMSW, CMAC, ACM, ACPA-C, introduces an Adaptive Model strategy that modernizes UM through role specialization, technology-driven workflows, and proactive, team-based processes. Attendees will learn how to restructure programs to improve efficiency, strengthen clinical collaboration, and enhance financial performance in a rapidly changing healthcare environment.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Celebrate Lab Week with MedLearn! Sign up to win one year of our Laboratory All Access Pass! Click here to learn more →
BLOOM INTO SAVINGS! Get 25% OFF during our spring sale through March 27. Use code SPRING26 at checkout to claim this offer.
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
